770 results match your criteria Human Vaccines [Journal]


Introduction of a second dose of measles in national immunization program in India: a major step towards eradication.

Hum Vaccin 2011 Oct;7(10):1109-11

Department of Community Medicine, Pt. B.D. Sharma PGIMS, Rohtak, India.

Measles is a highly infectious, acute respiratory illness that is caused by a virus of the genus Morbillivirus. The disease infects nearly 30 million children each year, and deaths usually occur from complications related to pneumonia, diarrhea and malnutrition. A systematic review of published Indian literature depicts the median case fatality ratio (CFR) of measles to be 1. Read More

View Article

Download full-text PDF

Source
October 2011
15 Reads
3.643 Impact Factor

Vaccination against trypanosomiasis: can it be done or is the trypanosome truly the ultimate immune destroyer and escape artist?

Hum Vaccin 2011 Nov;7(11):1225-33

Laboratory for Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium.

To date, human African trypanosomiasis (HAT) still threatens millions of people throughout sub-Sahara Africa, and new approaches to disease prevention and treatment remain a priority. It is commonly accepted that HAT is fatal unless treatment is provided. However, despite the well-described general symptoms of disease progression during distinct stages of the infection, leading to encephalitic complications, coma and death, a substantial body of evidence has been reported suggesting that natural acquired immunity could occur. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.11.18203DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3323498PMC
November 2011
5 Reads

Immune response to influenza vaccination in children treated with methotrexate or/and tumor necrosis factor-alpha inhibitors.

Hum Vaccin 2011 Dec 1;7(12):1293-8. Epub 2011 Dec 1.

Department of Pediatrics, University Children's Hospital, Bern, Switzerland.

In children treated with immunosuppressive medication such as methotrexate and tumor necrosis factor-alpha (TNF-α) inhibitors, additional immunizations are recommended because of increased susceptibility to infections. However, it is unclear if adequate antibody response to vaccinations can be established in children receiving methotrexate and/or TNF-α inhibitors. In a prospective open label study, we assessed seroprotection and seroconversion following influenza vaccination during 2 seasons (6 strains) in 36 children with autoimmune disease treated either with methotrexate (n=18), TNF-α inhibitors (n=10) or both (n=8) and a control group of 16 immunocompetent children. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.12.17981DOI Listing
December 2011
7 Reads

Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years.

Hum Vaccin 2011 Dec 1;7(12):1336-42. Epub 2011 Dec 1.

Merck Sharp & Dohme Corporation, Whitehouse Station, NJ, USA.

Background: Generating protective immune responses in older adults (particularly ≥65 y) remains challenging for vaccines in general. This study examined the immune response engendered in older adults by RECOMBIVAX HB™ manufactured using a modified adjuvant (modified-process hepatitis B vaccine; mpHBV), RECOMBIVAX-HB™, and ENGERIX-B™.

Methods: Randomized, double-blind, multicenter study enrolled healthy, seronegative subjects (N=538) to receive mpHBV (10 µg hepatitis B surface antigen [HBsAg]), RECOMBIVAX-HB™ (10 µg HBsAg), or ENGERIX-B™ (20 µg HBsAg) at Day 1, Month 1, and Month 6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.12.18333DOI Listing
December 2011
8 Reads

Fighting against infectious diseases in China.

Authors:
Weidong Yin

Hum Vaccin 2011 Dec 1;7(12):1250-3. Epub 2011 Dec 1.

Sinovac, Beijing, China.

Dr. Yin started his research on infectious disease prevention in the 1980s. In 1985, Dr. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.12.18971DOI Listing
December 2011
27 Reads

Hepatitis B Vaccine in national immunization schedule: a preventive step in India.

Hum Vaccin 2011 Dec 1;7(12):1387-8. Epub 2011 Dec 1.

Department of Community Medicine, Pt. B.D. Sharma PGIMS, Rohtak (Haryana), India.

Hepatitis B is a disease of the liver caused by Hepatitis B virus (HBV) infection. HBV is transmitted through contact with infected blood or body fluids, unprotected sexual intercourse and the perinatal route but not through casual contact. About two billion people worldwide have been infected with the virus, an estimated 360 million live with chronic infection, and at least 600,000 people die annually from acute or chronic consequences of Hepatitis B, such that Hepatitis B is a major public health problem worldwide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.12.17878DOI Listing
December 2011
9 Reads
3.643 Impact Factor

Human vaccines & immunotherapeutics.

Authors:
Ronald W Ellis

Hum Vaccin 2011 Oct;7(10):994

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.10.18260DOI Listing
October 2011
6 Reads

The continuing role of Haemophilus influenzae type b carriage surveillance as a mechanism for early detection of invasive disease activity.

Authors:
Susan P Jacups

Hum Vaccin 2011 Dec 1;7(12):1254-60. Epub 2011 Dec 1.

Research Institute for the Environment and Livelihoods, Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia.

Prior to the introduction of Haemophilus influenzae type b (Hib) conjugate vaccines, Hib was the leading cause of bacterial meningitis in children under five years of age worldwide. In countries that have adopted Hib vaccination schedules, invasive disease has reduced markedly. Oro-naso pharyngeal carriage is recognized as the most significant source of infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.12.17979DOI Listing
December 2011
4 Reads

Acceptance on the move: public reaction to shifting vaccination realities.

Authors:
Baruch Velan

Hum Vaccin 2011 Dec 1;7(12):1261-70. Epub 2011 Dec 1.

The Gertner Institute for Epidemiology and Health Policy Research, Tel-Hashomer, Israel.

This review examines four events related to vaccination that have occurred in recent years: (a) the ongoing recovery from the MMR/Autism scare in the UK, (b) the upgrading of the Varicella vaccine to a universal childhood vaccine, (c) the major effort of authorities to provide a vaccine for A/H1N1 influenza and its rejection by the public, and, d) the current attempts to change the HPV vaccine target from girls only to boys and girls. All of these changes have been met with shifts in the public acceptance of the relevant vaccine. These shifts are characterized not only by the number of people willing to be vaccinated, but also by the attitudes and the motives related to acceptance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.12.17980DOI Listing
December 2011
4 Reads

Approaches to improved targeting of DNA vaccines.

Hum Vaccin 2011 Dec 1;7(12):1271-81. Epub 2011 Dec 1.

State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu, China.

Proper targeting of DNA vaccines has been identified as a crucial factor in improving the efficacy of DNA vaccines. In general, targeting measures affect either directly the DNA or the protein(s) expressed by DNA vaccines towards antigen-presenting cells (APC) to enable efficacious antigen presentation via MHC class I and II pathways. Improved targeting of the delivery of antigen can significantly increase the protective effects and reduce vaccination doses and toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.12.17983DOI Listing
December 2011
3 Reads

Preventing mumps outbreaks in confined settings: comprehensive ring vaccination as a containment strategy.

Hum Vaccin 2011 Dec 1;7(12):1389-93. Epub 2011 Dec 1.

Braun Hebrew University-Hadassah School of Public Health and Community Medicine, Jerusalem, Israel.

Even among vaccinated cohorts, prevention and control of mumps outbreaks remain a challenge, owing to sub-optimal population immunity. This is especially true in confined settings, where a single case could be the index for an imminent outbreak. Efficacy of post-exposure prophylaxis has not been demonstrated, while early identification of mumps and comprehensive vaccination of populations in confined settings during outbreaks may enable containment of mumps and disrupt further spread. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.12.18111DOI Listing
December 2011
5 Reads
6 Citations
3.643 Impact Factor

Social and cultural determinants of anticipated acceptance of an oral cholera vaccine prior to a mass vaccination campaign in Zanzibar.

Hum Vaccin 2011 Dec 1;7(12):1299-308. Epub 2011 Dec 1.

Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland.

Despite improvements in sanitation and water supply, cholera remains a serious public health burden. Vaccination is included among recommendations for cholera control. Cultural concepts of illness are likely to affect vaccine acceptance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.12.18012DOI Listing
December 2011
10 Reads
10 Citations
3.643 Impact Factor

Pooled analysis of safety data from pediatric Phase II RTS,S/AS malaria candidate vaccine trials.

Hum Vaccin 2011 Dec 1;7(12):1309-16. Epub 2011 Dec 1.

GlaxoSmithKline Biologicals, Wavre, Belgium.

Prior to progression to Clinical Development Phase III, GlaxoSmithKline Biologicals performed a pooled analysis of phase two safety data following administration of 8860 doses of RTS,S/AS to 2981 children under 5 years old. RTS,S/AS was associated with increased rates of non-serious URTI, rash and diaper dermatitis graded mild or moderate. There was no significant increased rate of overall or single SAEs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.12.18046DOI Listing
December 2011
7 Reads

Determinants of tetanus and seasonal influenza vaccine uptake in adults living in Germany.

Hum Vaccin 2011 Dec 1;7(12):1317-25. Epub 2011 Dec 1.

Immunization Unit, Robert Koch Institute, Berlin, Germany.

The primary objective of this study was to assess determinants of vaccine uptake in adults living in Germany exemplified by one standard vaccination (tetanus) and one vaccination targeting specific risk-groups (seasonal influenza). Data from 21,262 telephone household-interviews representative of the adult population in Germany were collected in 2009 and analysed. A total 73. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.12.18130DOI Listing
December 2011
6 Reads

Peripheral immunization induces functional intrahepatic hepatitis C specific immunity following selective retention of vaccine-specific CD8 T cells by the liver.

Hum Vaccin 2011 Dec 1;7(12):1326-35. Epub 2011 Dec 1.

Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.

It is believed that an effective HCV vaccine must induce strong HCV-specific cytotoxic IFN-γ⁺ CD8⁺ T cells able to migrate into and become fully activated within the liver, an organ known to suppress T cell responses and induce tolerance. Given the importance of intrahepatic HCV-specific T cells in the clearance of acute infection, the goal of this present study was to determine if peripheral immunization was able to induce functional intrahepatic HCV-specific T cell based immunity both in the presence and absence of HCV antigen expression within the liver. Using a novel HCV NS3/NS4A DNA vaccine, we show that peripheral immunization of C57BL/6 mice results in the formation of a large pool of fully functional HCV-specific cytotoxic IFN-γ⁺ CD8⁺ T cells within the liver and that these cells were highly enriched within the liver as compared to the spleen. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.12.18279DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338931PMC
December 2011
11 Reads
3 Citations
3.640 Impact Factor

Rotavirus vaccines: update on global impact and future priorities.

Hum Vaccin 2011 Dec 1;7(12):1282-90. Epub 2011 Dec 1.

Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Early rotavirus vaccine adopter countries in the Americas, Europe, and in Australia have documented substantial declines in rotavirus disease burden following the introduction of vaccination.  However, the full public health impact of rotavirus vaccines has not been realized as they have not been introduced into routine immunization programs in countries of Africa and Asia with the highest rotavirus disease morbidity and mortality burden.  In this article, we review the epidemiology of rotavirus disease, the development and current status of rotavirus vaccines including newly available vaccine impact data from early-introducer countries, and future priorities for implementation and monitoring of rotavirus vaccination programs in developing countries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.12.18321DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338930PMC
December 2011
20 Reads

Pandemic influenza vaccination coverage in children with type 1 diabetes: analysis from seven Italian centers.

Hum Vaccin 2011 Dec 1;7(12):1291-2. Epub 2011 Dec 1.

Department of Pediatrics, University of Turin, Turin, Italy.

The pandemic influenza vaccination coverage in children with type 1 diabetes has been analysed. 1461 charts have been reviewed (788 M and 673 F, ages 13.0±4. Read More

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/abs/10.4161/hv.7.12.18335
Publisher Site
http://dx.doi.org/10.4161/hv.7.12.18335DOI Listing
December 2011
6 Reads

A history of hookworm vaccine development.

Hum Vaccin 2011 Nov 1;7(11):1234-44. Epub 2011 Nov 1.

Department of Microbiology, Immunology and Tropical Medicine, The George Washington University Medical Center; Washington, DC USA.

The human hookworms Necator americanus and Ancylostoma duodenale remain among the most common infections of humans in areas of rural poverty in the developing regions of the world, with an estimated 1 billion people infected with one or more of these parasites. Herein, we review the nearly 100 years of research, development, animal testing, and fieldwork that have led to our current progress in recombinant hookworm vaccines. We begin with the identification of hookworm at the start of the 20th century in Southern US, then discuss the progress in developed countries to eliminate human hookworm infection, and then the industrial development and field use in the 1970s a canine hookworm vaccine(Ancylostoma caninum), and finally our progress to date in the development and clinical testing of an array of recombinant antigens to prevent human hookworm disease from N. Read More

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/abs/10.4161/hv.7.11.18443
Publisher Site
http://dx.doi.org/10.4161/hv.7.11.18443DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3323499PMC
November 2011
21 Reads

Distribution of rotavirus genotypes causing nosocomial and community-acquired acute gastroenteritis at the Children's Hospital of Philadelphia in the new rotavirus vaccine era.

Hum Vaccin 2011 Nov 1;7(11):1118-23. Epub 2011 Nov 1.

The Children's Hospital of Philadelphia (CHOP), Philadelphia, PA, USA.

Background: Introduction of rotavirus vaccines in the United States beginning in 2006 led to a rapid decline in the frequency of acute rotavirus gastroenteritis necessitating medical attention. We examined whether serotype replacement was occurring as a result of vaccine use.

Methods: Children with gastroenteritis presenting to CHOP have been tested for rotavirus antigen in the stool. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.11.17820DOI Listing
November 2011
10 Reads

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.

Hum Vaccin 2011 Dec 1;7(12):1343-58. Epub 2011 Dec 1.

Department of Obstetrics & Gynecology and Women's Health, Division of Gynecologic Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.

In this observer-blind study (NCT00423046), women (N=1,106), stratified by age (18-26, 27-35, 36-45 y), were randomized (1:1) to receive the HPV-16/18 vaccine (Cervarix®, GlaxoSmithKline Biologicals, Months 0, 1, 6) or the HPV-6/11/16/18 vaccine (Gardasil® Merck & Co., Inc., Months 0, 2, 6). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.12.18281DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338932PMC
December 2011
21 Reads

Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years.

Hum Vaccin 2011 Dec 1;7(12):1359-73. Epub 2011 Dec 1.

Department of Obstetrics & Gynecology and Women's Health, Division of Gynecologic Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.

Protection against oncogenic non-vaccine types (cross-protection) offered by human papillomavirus (HPV) vaccines may provide a significant medical benefit. Available clinical efficacy data suggest the two licensed vaccines (HPV-16/18 vaccine, GlaxoSmithKline Biologicals (GSK), and HPV-6/11/16/18 vaccine, Merck & Co., Inc. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.12.18282DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338933PMC
December 2011
19 Reads

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study.

Hum Vaccin 2011 Dec 1;7(12):1374-86. Epub 2011 Dec 1.

University of Alberta, Edmonton, AB, Canada.

The immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine (Cervarix®, GlaxoSmithKline Biologicals) administered according to its licensed vaccination schedule (3-dose, 3D) and formulation (20 μg of each HPV antigen; 20/20F) has previously been demonstrated. This partially-blind, controlled, randomized trial (NCT00541970) evaluated 2-dose (2D) schedules using the licensed 20/20F or an alternative formulation containing 40 μg of each antigen (40/40F), compared with the licensed 3D schedule. Healthy females stratified by age (9-14, 15-19, 20-25 y) were randomized to receive 2 doses of 20/20F at Months (M) 0,6 (n=240), 40/40F at M0,6 (n=241) or 40/40F at M0,2 (n=240), or 3 doses of 20/20F at M0,1,6 (licensed schedule/formulation, n=239). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.12.18322DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338934PMC
December 2011
17 Reads

Advances and hurdles on the way toward a leprosy vaccine.

Hum Vaccin 2011 Nov 1;7(11):1172-83. Epub 2011 Nov 1.

Infectious Disease Research Institute, Seattle, WA USA.

Prevalence rates for leprosy have declined sharply over the past 20 y, with this decline generally attributed to the WHO multi-drug therapy (MDT) campaign to provide free-of-charge treatment to all diagnosed leprosy patients. The success of this program appears to have reached its nadir, however, as evidenced by the stalled decreases in both global prevalence and new case detection rates of leprosy. Mass BCG vaccination for the prevention of tuberculosis (TB) at national levels has had a positive effect on leprosy decline and is often overlooked as an important factor in current leprosy control programs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.11.16848DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3323495PMC
November 2011
3 Reads

Advances and challenges towards a vaccine against Chagas disease.

Hum Vaccin 2011 Nov 1;7(11):1184-91. Epub 2011 Nov 1.

Laboratorio de Parasitología, Centro de Investigaciones Regionales 'Dr. Hideyo Noguchi', Universidad Autónoma de Yucatán, Merida, Mexico.

Chagas disease is major public health problem, affecting nearly 10 million people, characterized by cardiac alterations leading to congestive heart failure and death of 20-40% of the patients infected with Trypanosoma cruzi, the protozoan parasite responsible for the disease. A vaccine would be key to improve disease control and we review here the recent advances and challenges of a T. cruzi vaccine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.11.17016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3323496PMC
November 2011
11 Reads

Schistosomiasis vaccines.

Hum Vaccin 2011 Nov 1;7(11):1192-7. Epub 2011 Nov 1.

Department of Microbiology and Immunology, Internal Medicine, Pathology, Texas Tech University Health Sciences Center, Lubbock, TX USA.

Schistosomiasis is a major neglected tropical disease of public health importance to a billion people. An estimated 200 million people are currently infected; an additional 779 million individuals are at risk to acquire the infection in 74 countries. Despite many years of implementation of mass anti-parasitic drug therapy programs and other control measures, this disease has not been contained and continues to spread to new geographic areas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.11.17017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3323497PMC
November 2011
5 Reads

H. pylori vaccines: why we still don't have any.

Hum Vaccin 2011 Nov 1;7(11):1153-7. Epub 2011 Nov 1.

Department of Medicine, Division of Gastroenterology, Rhode Island Hospital & Warren Alpert Medical School of Brown University, Providence, RI, USA.

Helicobacter pylori was appreciated as the major cause of peptic ulcers about 30 years ago and the most significant etiological agent in gastric cancer in the mid-1990s. Since that time, progress in the development of a preventive or therapeutic H. pylori vaccine has been relatively slow. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.11.17655DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360072PMC
November 2011
5 Reads

Haemophilus influenzae type b (Hib) vaccine: an effective control strategy in India.

Hum Vaccin 2011 Nov 1;7(11):1158-60. Epub 2011 Nov 1.

Department of Community Medicine, Pt. B.D. Sharma PGIMS, Rohtak, India.

Haemophilus influenzae type b (Hib) is an encapsulated, non-motile and non-spore-forming Gram-negative coccobacillus which causes severe pneumonia, meningitis and other life threatening illnesses. Hib disease affects almost exclusively (95%) children aged less than 5 years throughout the world. The mean age of onset is 6-24 months after which it declines gradually until age 5 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.11.17683DOI Listing
November 2011
13 Reads
3.643 Impact Factor

Buruli ulcer.

Hum Vaccin 2011 Nov 1;7(11):1198-203. Epub 2011 Nov 1.

WIV-ISP Site Ukkel, Service Immunology, Brussels, Belgium.

Buruli Ulcer (BU) is a neglected, necrotizing skin disease, caused by M. ulcerans, that can leave patients with prominent scars and lifelong disability. M. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.11.17751DOI Listing
November 2011
7 Reads

Leishmaniasis.

Hum Vaccin 2011 Nov 1;7(11):1204-14. Epub 2011 Nov 1.

Inflammation Division, Walter+Eliza Hall Institute of Medical Research, Department of Medical Biology, The University of Melbourne, Parkville, Australia.

Leishmaniasis is a disease that ranges in severity from skin lesions to serious disfigurement and fatal systemic infection. WHO has classified the disease as emerging and uncontrolled and estimates that the infection results in two million new cases a year. There are 12 million people currently infected worldwide, and leishmaniasis threatens 350 million people in 88 countries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.11.17752DOI Listing
November 2011
5 Reads

A novel adjuvant Ling Zhi-8 for cancer DNA vaccines.

Hum Vaccin 2011 Nov 1;7(11):1161-4. Epub 2011 Nov 1.

Graduate Institute of Immunology, College of Medicine, National Taiwan University, Taipei, Taiwan.

DNA vaccines have a wide range of applications, with several potential advantages compared to other vaccine technologies for diseases. No DNA vaccine has yet been licensed in humans; however, a lot of effort has been made to enhance their potential as human vaccines and therapeutics. Finding an effective adjuvant is a strategy to improve the efficacy of DNA vaccines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.11.17753DOI Listing
November 2011
28 Reads

Candida vaccines development from point view of US patent application.

Authors:
Shyh-Jen Wang

Hum Vaccin 2011 Nov 1;7(11):1165-71. Epub 2011 Nov 1.

Taipei Veterans General Hospital, Division of Experimental Surgery, Institute of Hospital and Health Care Administration National Yang-Ming University, Taipei, Taiwan.

Candidiasis is the fourth most common bloodstream infection in hospitalized patients in the United States. Moreover, the mortality rate from Candida infections remains high, even after treatment with antifungal therapy. Vaccination would be a promising strategy for prevention of invasive fungal infections. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.11.17821DOI Listing
November 2011
3 Reads

Relationship of therapeutic cancer vaccine development to population disease burden and five-year survival.

Hum Vaccin 2011 Nov 1;7(11):1124-9. Epub 2011 Nov 1.

University of Michigan Medical School, University of Michigan, Ann Arbor, MI USA.

In the United States, therapeutic vaccines may provide considerable benefit to cancer patients. Yet, there has been no assessment of whether vaccines currently in the research and development pipeline reflect the burden of disease and current survival patterns for different malignancies. The authors used data from the National Cancer Institute, Surveillance Epidemiology and End Results (SEER) database, and clinicaltrials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.11.17837DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3323492PMC
November 2011
25 Reads

Rural parents' vaccination-related attitudes and intention to vaccinate middle and high school children against influenza following educational influenza vaccination intervention.

Hum Vaccin 2011 Nov 1;7(11):1146-52. Epub 2011 Nov 1.

Emory University, Rollins School of Public Health, Atlanta, GA USA.

Objective: This study examined changes in parental influenza vaccination attitudes and intentions after participating in school-based educational influenza vaccination intervention.

Methods: Participants were drawn from three counties participating in a school-based influenza vaccination intervention in rural Georgia (baseline N=324; follow-up N=327). Data were collected pre- and post-intervention from phone surveys with parents' with children attending middle- and high-school. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.11.17891DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3323494PMC
November 2011
9 Reads

Recombinant vaccines against leptospirosis.

Hum Vaccin 2011 Nov 1;7(11):1215-24. Epub 2011 Nov 1.

Unidade de Biotecnologia, Centro de Desenvolvimento Tecnológico, Salvador, BA, Brazil.

Leptospirosis is an important neglected infectious disease that occurs in urban environments, as well as in rural regions worldwide. Rodents, the principal reservoir hosts of pathogenic Leptospira spp., and other infected animals shed the bacteria in their urine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.11.17944DOI Listing
November 2011
7 Reads

Safety and tolerability of zoster vaccine in adults ≥60 years old.

Hum Vaccin 2011 Nov 1;7(11):1130-6. Epub 2011 Nov 1.

PharmQuest, Greensboro, NC USA.

Objective: To evaluate the general safety of zoster vaccine (ZV) in adults ≥60 years old.

Patients/methods: Subjects were enrolled in a 1:1 ratio to receive 1 dose of ZV or placebo. Subjects were followed for serious adverse experiences (SAEs) for 42 days (primary follow-up period) and 182 days (secondary follow-up period) postvaccination. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.11.17982DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3323493PMC
November 2011
9 Reads

Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants.

Hum Vaccin 2011 Nov 1;7(11):1137-45. Epub 2011 Nov 1.

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Tlalpan, México.

The immunogenicity and safety of the 10-valent pneumococcal conjugate vaccine, PHiD-CV, have been documented in European and Asian studies. In this open study conducted in Mexico (NCT00489554), 230 healthy infants received three doses of PHiD-CV and DTPa-HBV-IPV/Hib vaccines at 2, 4 and 6 months of age and two doses of oral human rotavirus vaccine at 2 and 4 months. Serotype-specific pneumococcal responses and opsonophagocytic activity (OPA) were measured one month post-dose 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.11.17984DOI Listing
November 2011
12 Reads

Acceptability of school requirements for human papillomavirus vaccine.

Hum Vaccin 2011 Sep;7(9):952-7

Department of Epidemiology, Gillings School of Global Public Health, Chapel Hill, NC, USA.

We characterized parental attitudes regarding school HPV vaccination requirements for adolescent girls. Study participants were 866 parents of 10–18 y-old girls in areas of North Carolina with elevated cervical cancer incidence. We calculated odds ratios (ORs) and 95% confidence intervals (CIs) by logistic regression. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360068PMC
September 2011
6 Reads

A life passion for vaccines.

Hum Vaccin 2011 Aug;7(8):808-10

Research Center, Novartis Vaccines and Diagnostics, Siena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.8.17637DOI Listing
August 2011
4 Reads

Questions for biotechs: Oxford-Emergent Tuberculosis Consortium.

Authors:
Adam Stoten

Hum Vaccin 2011 Aug;7(8):806-7

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.8.17598DOI Listing
August 2011
5 Reads

Next generation vaccines.

Authors:
Eva M Riedmann

Hum Vaccin 2011 Jul;7(7):718-22

Landes Bioscience, Vienna, Austria.

In February this year, about 100 delegates gathered for three days in Vienna (Austria) for the Next Generation Vaccines conference. The meeting held in the Vienna Hilton Hotel from 23rd-25th February 2011 had a strong focus on biotech and industry. The conference organizer Jacob Fleming managed to put together a versatile program ranging from the future generation of vaccines to manufacturing, vaccine distribution and delivery, to regulatory and public health issues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.7.16976DOI Listing
July 2011
4 Reads

The effects of booster vaccination of hepatitis B vaccine on anti-HBV surface antigen negative children 11-15 years after primary vaccination.

Hum Vaccin 2011 Oct 1;7(10):1055-9. Epub 2011 Oct 1.

Department of Immune Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou, China.

The twin aims of this study were to investigate the changes in anti-HBs IgG levels after booster vaccinations and to compare the effects of different vaccine doses in children aged 11-15 years who were both negative for HBsAg and had an Anti-HBs < 10.0 mIU/mL after primary vaccination. Children who were born between 1993 and 1998 and who had completed their Hepatitis B vaccination program in infancy were randomly recruited to the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.10.15990DOI Listing
October 2011
9 Reads

Attitudes of seasonal influenza vaccination among healthcare worker and general community population after pandemic influenza A/H1N1 in Hangzhou.

Hum Vaccin 2011 Oct 1;7(10):1072-6. Epub 2011 Oct 1.

Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang, China.

Objective: To know the attitude toward seasonal influenza vaccination among healthcare worker (HCWs) and general community population (GCP s) in the post-pandemic influenza A/H1N1 period.

Results: A total of 489 participants including 126 HCWs and 363 GCP s completed the investigation. 33. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.10.16781DOI Listing
October 2011
3 Reads

Safety of a second dose of varicella vaccine administered at 4 to 6 years of age in healthy children in Argentina.

Hum Vaccin 2011 Oct 1;7(10):1066-71. Epub 2011 Oct 1.

Centros de Estudios Infectológicos, Buenos Aires, Argentina.

Varicela Biken [Live varicella Biken vaccine (strain Oka)] is an effective and safe vaccine for the prevention of varicella infection. Although the recommended schedule in all age groups (children, adolescents and adults) is a single dose, physicians in some countries follow the 2007 recommendation of the US Advisory Committee on Immunization Practices (ACIP) which recommends "implementation of a routine 2-dose varicella vaccination program for children, with the first dose administered at age 12--15 months and the second dose at age 4--6 years." ( 1) Therefore, cases can arise when two doses of Varicela Biken are given even though the ACIP guidelines are a response to the US epidemiological situation and for US licensed products based on the Oka/Merck and the Oka-RIT strains (Varicela Biken is not registered in US). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.10.17816DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256328PMC
October 2011
6 Reads

Two doses of pandemic influenza A(H1N1) vaccine: tolerability in healthy young children in the Netherlands.

Hum Vaccin 2011 Oct 1;7(10):1048-54. Epub 2011 Oct 1.

Department of Epidemiology and Surveillance, Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.

During the 2009 influenza pandemic, children aged 6 months up to and including 4 years, without chronic illness, were vaccinated with two doses of Pandemrix(®) through mass vaccination in the Netherlands. During the vaccination campaign a warning was issued about fever after the second dose of Pandemrix(®). Therefore, we investigated the tolerability of both doses Pandemrix(®) in these children. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.10.16692DOI Listing
October 2011
20 Reads

The stem cell patent landscape as relevant to cancer vaccines.

Authors:
Shyh-Jen Wang

Hum Vaccin 2011 Oct 1;7(10):1100-8. Epub 2011 Oct 1.

Division of Experimental Surgery, Department of Surgery, Veterans General Hospital-Taipei, Taiwan, China.

Cancer vaccine targeting cancer stem cells is proposed to serve as a potent immunotherapy. Thus, it would be useful to examine the main trends in stem cell patenting activity as a guide for those seeking to develop such cancer vaccines. We found that a substantial number of stem cell patents were granted up to the end of 2010, including ~2000 issued in the US. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.10.17022DOI Listing
October 2011
4 Reads

A passion for global vaccines.

Authors:
Seth Berkley

Hum Vaccin 2011 Jun;7(6):600-3

The International AIDS Vaccine Initiative, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.7.6.16841DOI Listing
June 2011
4 Reads